PhRMA Advises Members To Respect Independence Of Patient Organizations
This article was originally published in The Pink Sheet Daily
Executive Summary
Association’s principles on interactions with patient organizations says no company should require that it be the sole funder of a group.
You may also be interested in...
Patient Advocacy 3.0: Outreach Stretches to First Stages of Regulatory Development
FDA is ready to bring patient voices and perspectives into the drug approval framework. Practically, that means that drug sponsors will have to develop new skills and structures for working with a familiar stakeholder group at an unfamiliar point in the drug development process. The new challenge was a major theme at PhRMA’s 2012 Annual Meeting.
Supreme Court Seems To Support Government’s Later Dismissal Of False Claims Act Cases
Justices cite changing circumstances, constitutional concerns in preventing government from seeking dismissal of a case in which it initially declined to intervene. They also question whether government should intervene before moving to dismiss.
Battle Over Patents And Drug Pricing Engulfs FDA And USPTO
President Biden and Congress are pressuring the agencies to change patent policies so brand manufacturers cannot delay generic and biosimilar competition to keep monopoly prices. Timeline shows how they have responded to these demands.